Logo

OxMol Collaborates With Mitsubishi on Discovery

Dec 18, 1998
Premium

CAMPBELL, Calif.--The collaborative discovery division of Oxford Molecular Group, in a contract with Cambridge Combinatorial, announced that it will undertake a research program in drug discovery with Mitsubishi Chemical. The program aims to identify novel lead compounds for the treatment of metabolic disorders and utilizes the molecular design, medicinal chemistry, and combinatorial chemistry expertise of both companies. Mitsubishi will pay Oxford and Cambridge an undisclosed upfront payment, ongoing research fees, research milestones, and success payments in the drug development process, in addition to royalties on any compounds that are commercialized. Oxford also announced that it has invested £2.5 million in MicroGenics, a new company that will develop screening systems for novel antimicrobials.

Filed under

Informatics
Breaking News
The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.